"Analysis Shows Increased Risk Of Early Stroke With New-Onset Atrial Fibrillation Post-TAVR"
More than one-third of patients undergoing transcatheter aortic valve replacement (TAVR) were observed to have atrial fibrillation (AF) either at baseline or new-onset within 30 days after TAVR. The BRAVO-3 randomized trial was presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions in New Orleans.
"Previous studies have shown that AF patients undergoing TAVR have a greater risk for ischemic as well as bleeding events," said the study's principal investigator George D. Dangas, MD, PhD, an assistant professor of cardiology at the Icahn School of Medicine at Mount Sinai. "Our study showed that a large percentage of patients have AF, either baseline or new-onset," said study investigator Usman Baber, MD, assistant professor, medicine, cardiology Icahn School of Medicine at Mount Sinai.
- George Dangas, MD, PhD, Assistant Professor, Medicine, Cardiology, Surgery, Icahn School of Medicine at Mount Sinai, Director, Cardiovascular Innovation, Zena and Michael A. Wiener Cardiovascular Institute
- Usman Baber, MD, Assistant Professor, Medicine, Cardiology, Icahn School of Medicine at Mount Sinai
Learn more
